sarcosine has been researched along with Depressive Disorder, Major in 2 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the clinical study, sarcosine substantially improved scores of Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function more than citalopram treatment." | 5.17 | Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. ( Chang, YC; Chen, KT; Huang, CC; Huang, CL; Huang, KH; Lane, HY; Tsai, GE; Tsai, MH; Tsai, P; Tun, R; Wei, IH, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, CC | 1 |
| Wei, IH | 1 |
| Huang, CL | 1 |
| Chen, KT | 1 |
| Tsai, MH | 1 |
| Tsai, P | 1 |
| Tun, R | 1 |
| Huang, KH | 1 |
| Chang, YC | 1 |
| Lane, HY | 1 |
| Tsai, GE | 1 |
| Mathew, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder[NCT00977353] | Phase 2 | 40 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sarcosine and Depressive Disorder, Major
| Article | Year |
|---|---|
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
1 other study available for sarcosine and Depressive Disorder, Major
| Article | Year |
|---|---|
Glycine transporter-I inhibitors: a new class of antidepressant?
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Female; Glycine Plasma Membrane Transpor | 2013 |